



FINAL PROGRAM

Tuesday, June 10, 2008

19:00-21:00 Welcome Dinner: Melia Sitges

Wednesday, June 11, 2008

Morning Sessions

8:30 Opening remarks and introduction of plenary
John Mellors; University of Pittsburgh, USA

8:45 Diversity-Generating Retroelements
Jeffery F. Miller; UCLA School of Medicine, USA

RESISTANCE TO NEW ANTIVIRAL AGENTS

Chairs: Douglas Richman; VA San Diego Healthcare System and University of California San Diego, USA
François Clavel; Inserm U552, France

9:30 Potent HIV-1 Entry Inhibitors with a Reserve of Binding Energy Against Resistance Mutations
Michael Kay; University of Utah School of Medicine, USA

9:45 Resistance to CCR5mAb RoAb3952 is Associated with a Shift in Binding from the Extracellular Domain 2 to the N-Terminus of CCR5
Andreas Jekle; Roche Palo Alto, USA

10:00 Novel Resistance Profile of the Potent Nucleoside Analog Reverse Transcriptase Inhibitor 3'-Azido-2',3'-Dideoxyguanosine (AZG)
Jeffrey Meteer; University of Pittsburgh, USA

10:15 BREAK

10:45 Hexadecyloxypropyl tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile
Randall Lanier; Chimerix Inc., USA

- 11:00 In vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1-Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance
Robert Murphy; Northwestern University Feinberg School of Medicine, USA
- 11:15 Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients
Michael Miller; Merck & Co., Inc., USA
- 11:30 Loss of Raltegravir Susceptibility in Treated Patients is Conferred by Multiple Non-overlapping Genetic Pathways.
Signe Fransen; Monogram Biosciences, USA
- 11:45 HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457)
Scott McCallister; Panacos Pharmaceuticals, USA

12:00 LUNCH

Wednesday, June 11, 2008

Afternoon Sessions

- 13:30-16:00 Poster Viewing Session
Resistance to New Antiretroviral Agents and Clinical Implications of Resistance
- 16:00-17:00 Themed Discussion: **Resistance and Cross-Resistance Among HIV-1 Integrase Inhibitors**
Victoria Johnson; University of Alabama at Birmingham School of Medicine, USA

Free evening to enjoy Sitges

Thursday, June 12, 2008

Morning Sessions

- 8:30 Introduction of plenary
Charles Boucher; Erasmus Medical Center Rotterdam and University Hospital Utrecht, the Netherlands
- 8:45 Cellular cofactors of HIV integrase as novel antiviral targets
Zeger Debyser; K.U. Leuven, Belgium

MECHANISMS OF HIV DRUG RESISTANCE

Chairs

Brendan Larder; RDI, UK

Mark Wainberg; McGill University AIDS Centre, Canada

- 9:30 Mechanism by which the HIV Integrase Active Site Mutation N155H Confers Resistance to Raltegravir
Jay Grobler; Merck Research Laboratories, USA
- 9:45 Structural Explanations to Altered Drug Resistance Pathways in HIV-1 Non-Clade B Proteases
Rajintha Bandaranayake; University of Massachusetts Medical School, USA
- 10:00 How HCV NS3-4A Protease R155K/T Strains Can Discriminate VX-950 but affect differentially SCH-503034
Jerome Courcabeck; GenoScience, France
- 10:15 BREAK
- 10:30 Structural Basis for K65R Function: Tenofovir Resistance, Reduced Nucleotide Incorporation and Excision Antagonism
Kalyan Das; CABM & Rutgers University, USA
- 10:45 AZT Resistance Related Connection Mutations in HIV-1 RT Cause Selective Dissociation from RNase H-Competent Complexes
Maryam Ehteshami; McGill University, Canada
- 11:00 Q509L in HIV-1 RT Increases AZT Resistance by Promoting Polymerase-Competent vs. RNase H-Competent Binding on RNA/DNA T/P with Short Duplex Lengths
Jessica Brehm; University of Pittsburgh, USA
- 11:15 Evolution of Reverse Transcriptase Connection Domain Mutations in Patients on Antiretroviral Therapy
Viktor von Wyl; University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, Switzerland
- 11:30 Delayed Chain-Termination Protects the HBV Drug Entecavir from Excision by HIV-1 Reverse Transcriptase
Matthias Götte; McGill University, Canada
- 12:00 LUNCH

Thursday, June 12, 2008

Afternoon Sessions

- 13:30-16:00 Poster Viewing Session
Epidemiology, HBV/HCV Drug Resistance, and Mechanisms of HIV Drug Resistance
- 16:00-17:00 Themed Discussion: In depth genetic analyses of virus populations
Richard Haubrich; University of California, San Diego, USA
- 19:00-21:00 Dinner: Melia Sitges

Friday, June 13, 2008

Morning Sessions

HIV PATHOGENESIS, FITNESS AND RESISTANCE

Chairs: Charles Boucher; Erasmus Medical Center Rotterdam and University Hospital Utrecht, the Netherlands
Daniel Kuritzkes; Brigham and Women's Hospital, USA

- 8:30 Single Cell Analysis of HIV DNA from Infected Patients
Sarah Palmer; Karolinska Institute, Sweden
- 8:45 Correlations between Transmitted HIV-1 Drug Resistance Mutations and the HLA Alleles of Therapy-Naïve HIV-Patients
Rolf Kaiser; University of Cologne, Germany
- 9:00 HIV-1 Recombination in Patients Infected with Multiple HIV-1 Variants from the Same Donor
Mary Kearney; National Cancer Institute, USA
- 9:15 The selection, transmission and persistence of drug-resistant HIV-1 in infants prophylaxed with single-dose nevirapine (sdNVP) varies by the timing of infection
Ana Judith Blanco; Health Alliance International, USA
- 9:30 Intensification with Efavirenz or Lopinavir/Ritonavir Does Not Reduce Residual HIV-1 Viremia in Patients on Standard Antiretroviral Therapy
Frank Maldarelli; HIV Drug Resistance Program, USA

NEW RESISTANCE TECHNOLOGIES AND INTERPETATIONS

Chairs: Brendan Larder; RDI, UK
Christos Petropoulos; Monogram Biosciences, USA

- 10:00 Dynamic HIV-1 Escape from Vicriviroc Therapy in vivo
Athe Tsibris; Massachusetts General Hospital, USA
- 10:15 Response to Vicriviroc (VCV) in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay [Trofile (ES)]: Reanalysis of ACTG 5211 Results
Jacqueline Reeves; Monogram Biosciences, USA
- 10:30 BREAK

- 11:00 Improved Detection Of X4 Virus By V3 Genotyping: Application To Plasma RNA And Proviral DNA
Richard Harrigan; BC Centre for Excellence in HIV/AIDS, Canada
- 11:15 Improved Genotypic Prediction Of HIV-1 Coreceptor Usage By Incorporating V2 Loop Sequence Variation
Alexander Thielen; Max-Planck Institute for Informatics, Germany
- 11:30 Inferring viral tropism from genotype with massively parallel sequencing: Qualitative and quantitative analysis
Martin Daumer; Institute of Immunology and Genetics, Germany

CLINICAL IMPLICATIONS OF RESISTANCE

Chairs: John Mellors; University of Pittsburgh, USA
Carlo-Federico Perno; University of Rome "Tor Vergata", Italy

- 11:45 Emergence of drug resistance after failure of first line HAART is associated with intensity of virological monitoring: A systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy
Ravindra Gupta; Royal Free and University College Medical School ,University College London, UK
- 12:00 Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy
Gillian Hunt; National Institute for Communicable Diseases, South Africa
- 12:15 Determination of Phenotypic Clinical Cut-offs for Etravirine: Pooled Week 24 Results of the DUET-1 and DUET-2 trials
Monika Peeters; Tibotec BVBA, Belgium
- 12:30 Biological and Clinical Cutoff Analyses for Etravirine in the PhenoSense™ HIV Assay
Eoin Coakley; Monogram Biosciences, USA
- 12:45 LUNCH

Friday, June 13, 2008

Afternoon Sessions

- 13:30-16:00 Poster Viewing Session
HIV Pathogenesis, Fitness/Resistance and New Resistance Technologies and Interpretations
- 16:00-17:00 Themed Discussion: Emerging epidemiology of drug resistance in the developing world
Deenan Pillay; University College London, UK**
- 17:00 Closing Remarks
- 20:00-23:00 Awards Dinner: Cavas Codorniu